History
A 32-year-old Caucasian male reported to the office with a chief complaint of vision loss in the left eye following trauma received during a basketball game. 

The patient explained that he had been hit around the left eye with an elbow during a game. Immediately follwing the injury he saw an “impressive” flash of light and, ever since then, said he felt as if some of the floor was “missing” or “foggy.” 

The patient’s systemic and ocular histories were unremarkable and he denied exposure to chemicals or allergies of any kind.

Diagnostic Data
His best-corrected entering visual acuities were 20/20 OU at distance and near. His external examination was normal with no evidence of afferent pupillary defect. 

His peripheral confrontational visual field exam found distorted and missing floor in the inferior temporal quadrant. 

The biomicroscopic examination of the patient’s anterior segments found normal structures. Using Goldmann applanation tonometry, his intraocular pressure was measured at 15mm Hg OU. 

The pertinent posterior segment findings are shown in the accompanying fundus photograph. 

Your Diagnosis
Does this case require any additional tests? What does this patient’s history and clinical findings tell you about his likely diagnosies? How would you manage this patient? What’s the patient’s likely prognosis? 

Discussion
Additional testing should include 3-mirror lens evaluation of the peripheries of both eyes to identify new and old retinal tears and holes. Photodocumentation should be completed with standard photography. Optos technology and optical coherence tomography (OCT) are excellent adjunctive tools.

Additional historical questions should include “has this happened before to you in the same eye, fellow eye or any member of the family?”

The diagnosis in this issue is trauma-based rhegmatogenous retinal detachment. Retinal detachments occur in approximately 6.1:100,000 persons in the general phakic population.1-3 The rates between men and women are similar worldwide, with a slight preponderance for female gender with myopia.2-4

There are three recognized forms of retinal detachment.1-9 These include:

  • Rhegmatogenous retinal detachment (RRD-resulting from a retinal break).
  • Exudative (or serous) retinal detachment (ERD-resulting from fluid accumulation under the sensory retina without a retinal break).
  • Tractional retinal detachment (TRD-resulting from the pull of proliferative fibrovascular vitreal strands).1-10

Rhegmatogenous retinal detachments may be asymptomatic.11,12 In symptomatic RRD patients report photopsiae (flashes of light), floating spots, peripheral visual field loss (curtain phenomenon) and depending upon the involvement of the macula, central blurring of vision with or without metamorphopsia.1,13 There are anecdotal reports of exudative retinal detachments producing photopsiae (flashing purple lights), but the common symptom experienced by these patients is vision loss and metamophopsia consistent with the degree of macular involvement, with or without a visual field deficit.5,14 Tractional retinal detachments have the capacity to produce the same symptoms as rhegmatogenous and exudative retinal detachments. They may also remain asymptomatic until central vision is threatened.5,15 Pain is not a feature of retinal detachment.12 Any pain encountered by a patient experiencing any form of retinal detachment is secondary to an associated cause such as headache, iritis, corneal abrasion, uveitis or raised intraocular pressure and not the detachment itself.1,5,16,17 Extensive unilateral retinal detachment will produce a relative afferent pupillary defect.1,16 Intraocular pressure may be notably reduced in eyes with acute retinal detachment.19-21



This 32-year-old patient lost vision following trauma received during a basketball game. Can this dilated fundus photo help determine a diagnosis?

Clinical observation of fresh RRD usually reveals a clumping of pigment cells within the vitreous (Shaffer’s sign/tobacco dust) adjacent to the retinal break.1,22 An area of white or grayish elevated retina may be seen adjacent to the instigating retinal break secondary to influx of subretinal fluid (SRF).4 If a significant area of the retina is involved it may appear bullous and undulating. A rhegmatogenous detachment is produced by a retinal break that becomes expanded by poorly understood posterior segment fluid mechanics.21 Osmotic and oncotic pressures help keep the retina in place.22 As such, RRD do not change positions when body posture is altered.23 RRD do shift and return to their original orientation with quick eye movements.1 Associated findings of RRD may include posterior vitreous detachment and preretinal or vitreal hemorrhage.24-26 Retinal pigment epithelial hyperplasia may be noted in cases of long-standing retinal detachment of any kind (pigment demarcation line). Increased RPE density is a feature of attempted self repair.1,5,27

Exudative retinal detachments (ERD) appear as focal, serous elevations of the retina in the absence of retinal breaks.5,28-34 Because the fluid is contained underneath an intact neurosensory boundary, the bullous separation possesses the characteristic of following gravity, shifting position with changes in posture and eye movement.1,5 Ophthalmoscopic observation reveals a smooth, translucent, dome-shaped protrusion of the retina along with variable other signs secondary to the causative etiology (blood, exudate, serosanguinous fluid, etc…).5 Causes of ERD include Coat’s disease, age-related macular degeneration, idiopathic central serous chorioretinopathy (ICSC), fluid exudation from chroidal tumors and Vogt-Koyanagi Harada syndrome.5,28-34

Tractional retinal detachment (TRD) is always associated with fibrovascular vitreal strands and membranes.1,35-37 The clinical appearance of these detachments is varied with tangential fibrovascular bands anchoring into the vitreous body and extending to the disinserted retina.1,35-37 The tractional membranes may encircle intact retina, resulting in a “pseudo-hole” appearance. TRDs are dense and immobile, as compared with ERD and RRD. Any pathology that can induce posterior segment ischemia and intraretinal neovascularization can proceed to TRD. The common underlying causes include diabetes, vein occlusion, ocular ischemic syndrome, retinopathy of prematurity and sickle cell disease.35-39

Pathophysiology
All retinal detachments involve a dissection of the sensory retina from its underlying pigment epithelial layer by SRF.1-40 In rhegmatogenous detachments this fluid is thought to be composed of liquefied vitreous, which gains access to the subretinal space via a retinal break.1,22 In exudative detachments, the fluid is derived from the choroid, passing through a breach in Bruch’s membrane.5,28-34 The origin of the subretinal fluid in tractional retinal detachments is similar with slightly varied mechanisms. Generally, altered balance between the passive and active movement of SRF induces RD progression.1 While all retinal detachments have the potential to produce visual scotomata (depending upon their size and location), it is the involvement of the macular region, where apoptotic mechanisms deteriorate macular photoreceptors, that will determine the extent of acuity loss.40

Retinal breaks are the predisposing factor in patients with rhegmatogenous retinal detachment.1,22-27 These may occur spontaneously from preexisting conditions or as a result of ocular trauma.1-3 Some of the common entities associated with RRD include lattice degeneration, flap tears, atrophic holes, operculated retinal breaks and acquired retinoschisis with both inner and outer holes.1,3,4,41 As the retinal tissue loses its connection to the RPE, it becomes edematous and dysfunctional.22 The detached retina loses its oxygen supply and relies on anaerobic pathways to metabolize glucose.22 Long-duration retinal detachments feature increased lactic acid and dextrose concentrations.23 Phospholipids are also increased in the subretinal fluid, reflecting retinal organelle degradation.23 Eventually, photoreceptor death occurs within 48-72 hours unless surgical intervention is employed.23,40

Exudative retinal detachments occur in association with subretinal disorders which damage the RPE layer.5,28-34 These may include: ICSC, choroidal neoplasms, Vogt-Koyanagi-Harada syndrome, posterior scleritis, congenital optic disc anomalies (optic pits, morning glory syndrome, etc.), Coat’s disease, and uveal effusion syndrome.5,28-34 Transudation of fluid from the choroidal reservoir through Bruch’s membrane and a breach in the retinal pigment epithelium (RPE) overcomes the eye’s natural mechanisms for deturgessing the plasma solution, causing it to build under the photoreceptors. When the threshold is reached it causes them to disinsert from the RPE.5,23,28-34 Affected by gravity, as the fluid accumulates, the detachment will shift with eye and head movements. However, since the density of fluid affecting the retina changes with movement, no particular area of the retina is continuously affected.5 This may explain why patients with ERD do better than those with RRD or TRD.5,28-34

Tractional retinal detachments occur in the presence of proliferative vitreoretinopathies.1,35-39 The most common of these disorders is proliferative diabetic retinopathy. TRDs may also be found in association with ischemic retinal vein occlusions, sickle cell retinopathy, retinopathy of prematurity and trauma.1,35-37 The etiology of TRD involves fibrotic scaffolding of the vitreous along proliferative vascular networks, which through vitreal shrinkage, induce strong anterior tractional forces.39,42-44 RPE cell proliferation and migration are believed to play a role in the pathogenesis.43 Findings suggest that the vitreous contributes modulators that stimulate RPE cells along with macrophages, fibroblasts and glial cells to interact with constituents of the extracellular matrix such as fibronectin, vitronectin, and factor XIII.43,44 These mechanisms induce the formation of membranes that capture the sensory retina and forcibly separate it from the underlying RPE.39,42-44 Unlike rhegmatogenous or exudative retinal detachments which tend to occur acutely, TRD often develop slowly. When positioned peripherally TRD may not be noticed by the patient until visual acuity is compromised by the underlying disease process.

Management
Retinal detachments demand repair and treatment of both the retina and the underlying cause.1-49 Patients presenting with an acute onset RRD involving or threatening the macula warrant an immediate and emergent referral to retinology. Fresh RRD should be repaired within 24 to 48 hours; chronic or long-standing RRD or RRD that do not threaten the macula should be addressed within one week of diagnosis.50,51 Small peripheral RRD secondary to atrophic holes or RRD secondary to small tears displaying minimal SRF may be managed with barrier laser photocoagulation or cryopexy.1,45-49 While cryopexy has been reported to provoke a more aggressive post operative inflammatory response, its outcomes over time compared to laser barrier treatment are similar.49 An advantage of cryopexy over laser procedures is that it is generally less expensive and does not have to be repeated.49 Larger RRD require surgical repair using procedures that include vitrectomy, scleral buckling, needle aspiration, laserpexy, cryopexy, pneumatic retinopexy and intraocular silicone oil tamponade.13,52-55

Vitrectomy has been investigated as a principle treatment method for RRD.56-58 Vitrectomy seems to allow improved control of more complicated situations.57 The Scleral Buckling Versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment Study (SPR study)56,58 is a prospective, randomised, multicenter study comparing primary vitrectomy with or without additional scleral buckling to scleral buckling alone.56,58 In the pseudophakic subgroup, no difference in functional outcome was seen; however, better anatomical results with a lower rate of retina-affecting reoperations was observed in the vitrectomy group.56-58 Based on this data, primary vitrectomy combined with a scleral buckle is the method of choice in complicated retinal detachment in pseudophakic patients. In contrast, primary vitrectomy does not seem to offer an advantage over scleral buckling in phakic patients.56,58 The primary drawback of vitrectomy is its significant propensity to create cataract and postpone complete visual recovery.58

Scleral buckling is accomplished under general anesthesia where a soft silicone sponge or hard silicone band is used to indent the eye at the location of detachment.59 The intent of the buckle (explant-on top of the sclera, implant-placed into a scleral dissection) is to eliminate the vitreoretinal traction that induced the retinal tear and to prevent fluid seepage underneath the retinal break.1,59 This process also encourages RPE pumping to eliminate the SRF. Drainage of SRF via syringe is controversial with some believing it is not necessary and others believing it is crucial.58 Raised IOP, choroidal detachment, diplopia, macular edema and macular pucker are all potential complications.59

Pneumatic retinopexy utilizes an intravitreal gas bubble (usually perfluoropropane, C3F8 or sulfahexafluoride) to achieve reattachment of the retina.60-62 This technique is performed under local anesthesia and is more common for treating smaller, superiorly located detachments.60 Careful eye and head positioning are important post-operatively to ensure resolution.60 In certain instances, silicone oil tamponade may be favorable to either of the aforementioned techniques.63 The use of polydimethylsiloxane (PDMS) as a silicone oil endotamponade has become a gold standard in retinal surgery.63 In cases of complicated inferior and posterior retinal detachment heavy silicone oils are sometimes considered.63 The Heavy silicone oil versus standard silicone oil as vitreous tamponade in inferior PVR (HSO Study) was a randomized prospective clinical trial comparing heavy and standard silicone oil in patients with PVR of the lower retina.64 The intermediate results have failed to demonstrate superiority of a heavy oil tamponade.64

Exudative detachments, because of their nature, generally require less intervention than RRD.5,7 ERDs may resolve spontaneously or following management of the underlying condition.5,7,23,28-34 This may involve oral antibiotics in cases involving infection, high dose oral or vitreal injectable/implantable corticosteroids in the case of inflammatory disorders, oral acetozolomide in cases of ICSC and radiation therapy and/or local resection in the case of intraocular neoplasms.65-67 In cases involving choroidal neovascularization laser photocoagulation, photodynamic therapy and vascular endothelial growth factor inhibitor injections (VEGFI) may all be attempted.65,68

Tractional retinal detachments are more difficult to manage than either RRD or ERD. Managing the underlying cause is an essential precursor.39,35-37 Endolaser scatter photocoagulation must be employed directly to the retina to correct the underlying inciting retinal cause for new vessel growth.39 Surgical repair of TRD involves pars plana vitrectomy to remove the traction and the fibrovascular membranes along with the inciting vitreal cytokines. Gas or oil tamponade is used to promote retinal reattachment.63,64,69 

Clinical Pearls:

  • All patients presenting with symptoms of retinal detachment or a predisposing history (peripheral retinal thinning or breaks, blunt ocular trauma, proliferative diabetic vitreoretinopathy, etc.) must undergo a thorough dilated fundus evaluation, with scleral indentation where appropriate.
  • Fresh rhegmatogenous detachments should be immediately referred for evaluation by retinology for surgical intervention.
  • The effect of gravity increases the risk for superior detachments to spread.
  • Conservative surgical management may be indicated for partial or sectoral RRD (laser barrier).
  • Exudative retinal detachments are produced by ophthalmologic conditions which often require co-management with ophthalmology.
1. Wilkinson CP. Rhegmatogenous retinal detachment. In: Yanoff M, Duker JS. Ophtalmology 2nd Ed. Mosby, Philadelphia, 2004:982-989.
2. Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment.Arch Ophthalmol. 1982;100(2):289-92.
3. Mitry D, Charteris DG, Fleck BW, Campbell H, et al. The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations. Br J Ophthalmol. 2010;94(6):678-84.
4. Ung T, Comer MB, Ang AJ, Sheard R, et al. Clinical features and surgical management of retinal detachment secondary to round retinal holes. Eye (Lond). 2005;19(6):665-9.
5. Anand R. Serous detachment of the neural retina. In: Yanoff M, Duker JS. Ophtalmology 2nd Ed. Mosby, Philadelphia, 2004: 990-996.
6. Saika S, Yamanaka O, Okada Y, Tanaka S, et al. TGF beta in fibroproliferative diseases in the eye. Front Biosci (Schol Ed). 2009;1(6):376-90.
7. Srećković SB, Janićijević-Petrović MA, Stefanović IB, et al. Bilateral retinal detachment in a case of preeclampsia. Bosn J Basic Med Sci. 2011;11(2):129-31.
8. Fluieraru R. Ocular, anatomical and functional changes in rhegmatogenous retinal detachment. Oftalmologia. 2008;52(2):39-43.
9. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010;24(12):1743-56.
10. Mitry D, Fleck BW, Wright AF, Campbell H, et al. Pathogenesis of rhegmatogenous retinal detachment: predisposing anatomy and cell biology. Retina. 2010;30(10):1561-72.
11. Ahmad N, West J. Current opinion on treatment of asymptomatic retinal detachments. Eye (Lond). 2007;21(9):1179-85.
12. Brod RD, Flynn HW Jr, Lightman DA. Asymptomatic rhegmatogenous retinal detachments. Arch Ophthalmol. 1995;113(8):1030-2.
13. Colucciello M. Rhegmatogenous retinal detachment. Phys Sportsmed. 2009;37(2):59-65.
14. Kim YY, Flaxel CJ. Factors influencing the visual acuity of chronic central serous chorioretinopathy. Korean J Ophthalmol. 2011;25(2):90-7.
15. Creuzot-Garcher C, Wolf S. Macular edema. Miscellaneous. Dev Ophthalmol. 2010;47(1):183-98.
16. Waters T, Vollmer L, Sowka J. Proliferative vitreoretinopathy as a late complication of blunt ocular trauma. Optometry. 2008;79(4):197-202.
17. Beran DI, Murphy-Lavoie H. Acute, painless vision loss. J La State Med Soc. 2009;161(4):214-6, 218-23.
18. Uysal Y, Mutlu FM, Sobaci G. Ocular Trauma Score in childhood open-globe injuries. J Trauma. 2008;65(6):1284-6.
19. Tan HS, Mura M, Oberstein SY, de Smet MD. Primary retinectomy in proliferative vitreoretinopathy. Am J Ophthalmol. 2010;149(3):447-52.
20. Grigoropoulos VG, Benson S, Bunce C, Charteris DG. Functional outcome and prognostic factors in 304 eyes managed by retinectomy. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):641-9.
21. Lin YC, Chang WH, Yang CM. Complications and management of post-vitrectomy circumferential retinal detachment. J Formos Med Assoc. 2009;108(4):333-6.
22. Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol. 1978;62(11):737-47.
23. Quintyn JC, Brasseur G. Subretinal fluid in primary rhegmatogenous retinal detachment: physiopathology and composition. Surv Ophthalmol. 2004;49(1):96-108.
24. Hollands H, Johnson D, Brox AC, Almeida D. Acute-onset floaters and flashes: is this patient at risk for retinal detachment? JAMA. 2009;302(20):2243-9.
25. Margo CE, Harman LE. Posterior vitreous detachment. How to approach sudden-onset floaters and flashing lights. Postgrad Med. 2005;117(3):37-42.
26. Mitry D, Singh J, Yorston D, Siddiqui MA, et al. The predisposing pathology and clinical characteristics in the Scottish retinal detachment study. Ophthalmology. 2011;118(7):1429-34.
27. Hara A, Nakagomi Y. Analysis of glycosaminoglycans of subretinal fluid in rhegmatogenous retinal detachment--preliminary report. Jpn J Ophthalmol. 1995;39(2):137-42.
28. Mennel S, Meyer CH, Peter S, Schmidt JC, et al. Current treatment modalities for exudative retinal hamartomas secondary to tuberous sclerosis: review of the literature. Acta Ophthalmol Scand. 2007;85(2):127-32.
29. Vrabec TR, Augsburger JJ. Exudative retinal detachment due to small noncalcified retinal astrocytic hamartoma. Am J Ophthalmol. 2003;136(5):952-4.
30. Perez MA, Shechtman DL, Gurwood A. The continuum of primary retinal telangiectasia. Optometry. 2011;82(3):158-65.
31. Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol. 2001;131(5):561-71.
32. Wang GH, Zhang J, Zhang D, Lv FL, et al. Value of three-dimensional optical coherence tomography and fundus photochromy in correlating the fluorescein leaking sites of acute central serous chorioretinopathy. Med Princ Pract. 2011;20(3):283-6.
33. Lim JH, Lee YN, Kim YS, Kim SG, et al. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol. 2011;17(1):61-5.
34. Errera MH, Fardeau C, Cohen D, Navarro A, et al. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease. Acta Ophthalmol. 2011;89(4):e357-66.
35. Newman DK. Surgical management of the late complications of proliferative diabetic retinopathy. Eye (Lond). 2010;24(3):441-9.
36. Fletcher EL, Downie LE, Ly A, Ward MM, et al. A review of the role of glial cells in understanding retinal disease. Clin Exp Optom. 2008;91(1):67-77.
37. Jalil A, Dhawahir-Scala FE, Jones NP. Nonprogressive tractional inferior retinal elevation in intermediate uveitis. Ocul Immunol Inflamm. 2010;18(1):60-3.
38. Micelli Ferrari T, Furino C, Lorusso VV, Dammacco R, et al. Three-port lens-sparing vitrectomy for aggressive posterior retinopathy of prematurity: early surgery before tractional retinal detachment appearance. Eur J Ophthalmol. 2007;17(5):785-9.
39. Ebroon DA, Bearelly S, Jampol LM. Proliferative retinopathies. In: Yanoff M, Duker JS. Ophtalmology 2nd Ed. Mosby, Philadelphia, 2004: 907-911.
40. Lo AC, Woo TT, Wong RL, Wong D. Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica. 2011;226(1); Suppl 1:10-17.
41. Martínez-Castillo V, Boixadera A, Verdugo A, et al. Rhegmatogenous retinal detachment in phakic eyes after posterior chamber phakic intraocular lens implantation for severe myopia. Ophthalmology. 2005;112(4):580-5.
42. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology. 1987;94(4):327-32.
43. Kirchhof B, Sorgente N. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev Ophthalmol. 1989;16(1):1-53.
44. Wiedemann P, Weller M, Heimann K. Proliferative vitreoretinopathy: new discoveries in pathophysiology and therapy. Klin Monbl Augenheilkd. 1990;197(5):355-61.
45. Shukla D, Maheshwari R, Kim R. Barrage laser photocoagulation for macula-sparing asymptomatic clinical rhegmatogenous retinal detachments. Eye (Lond). 2007;21(6):742-5.
46. Hwang JF, Chen SN. Demarcation laser photocoagulation of macular sparing retinal detachments in teenagers. Retina. 2008;28(10):1487-92.
47. Eliott D, Hauch A, Kim RW, Fawzi A. Retinal dialysis and detachment in a child after airbag deployment. J AAPOS. 2011;15(2):203-4.
48. Lira RP, Takasaka I, Arieta CE, Nascimento MA, et al. Cryotherapy vs laser photocoagulation in scleral buckle surgery: A randomized clinical trial. Arch Ophthalmol. 2010;128(12):1519-22.
49. Veckeneer M, Van Overdam K, Bouwens D, Feron E, et al. Randomized clinical trial of cryotherapy versus laser photocoagulation for retinopexy in conventional retinal detachment surgery. Am J Ophthalmol. 2001;132(3):343-7.
50. Henrich PB, Priglinger S, Klaessen D, Kono-Kono JO, et al. Macula-off retinal detachment--a matter of time? Klin Monbl Augenheilkd. 2009;226(4):289-93.
51. Mowatt L, Shun-Shin GA, Arora S, Price N. Macula off retinal detachments. How long can they wait before it is too late? Eur J Ophthalmol. 2005;15(1):109-17.
52. Greven CM. Retinal breaks. In: Yanoff M, Duker JS. Ophtalmology 2nd Ed. Mosby, Philadelphia, 2004: 978-981.
53. Kitchens JW. Modified external needle drainage of subretinal fluid in the management of rhegmatogenous retinal detachment using a "guarded needle" approach. Arch Ophthalmol. 2011;129(7):949-51.
54. Bourla DH, Bor E, Axer-Siegel R, Mimouni K, et al. Outcomes and complications of rhegmatogenous retinal detachment repair with selective sutureless 25-gauge pars plana vitrectomy. Am J Ophthalmol. 2010;149(4):630-634.
55. Al-Khairi AM, Al-Kahtani E, Kangave D, Abu El-Asrar AM. Prognostic factors associated with outcomes after giant retinal tear management using perfluorocarbon liquids. Eur J Ophthalmol. 2008;18(2):270-7.
56. Mehta S, Blinder KJ, Shah GK, Grand MG. Pars plana vitrectomy versus combined pars plana vitrectomy and scleral buckle for primary repair of rhegmatogenous retinal detachment. Can J Ophthalmol. 2011;46(3):237-41.
57. Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, et al. Primary pars plana vitrectomy. Techniques, indications, and results. Ophthalmologe. 2008;105(1):19-26.
58. Azad RV, Chanana B, Sharma YR, Vohra R. Primary vitrectomy versus conventional retinal detachment surgery in phakic rhegmatogenous retinal detachment. Acta Ophthalmol Scand. 2007;85(5):540-5.
59. Williams GA. Scleral buckling surgery. In: Yanoff M, Duker JS. Ophtalmology 2nd Ed. Mosby, Philadelphia, 2004: 786-791.
60. Davis MJ, Mudvari SS, Shott S, Rezaei KA. Clinical characteristics affecting the outcome of pneumatic retinopexy. Arch Ophthalmol. 2011;129(2):163-6.
61. Saw SM, Gazzard G, Wagle AM, Lim J, et al. An evidence-based analysis of surgical interventions for uncomplicated rhegmatogenous retinal detachment. Acta Ophthalmol Scand. 2006t;84(5):606-12.
62. Chan CK, Lin SG, Nuthi AS, Salib DM. Pneumatic retinopexy for the repair of retinal detachments: a comprehensive review (1986-2007). Surv Ophthalmol.2008;53(5):443-78.
63. Engelmann K, Herbrig E. Different endotamponade agents and their clinical indications. Klin Monbl Augenheilkd. 2008;225(2):138-45.
64. Joussen AM, Rizzo S, Kirchhof B, Schrage N, et al. Heavy silicone oil versus standard silicone oil in as vitreous tamponade in inferior PVR (HSO Study): interim analysis. Acta Ophthalmol. 2011;89(6):483-9.
65. Arevalo JF, Espinoza JV. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2011;249(8):1159-66.
66. Ossewaarde-van Norel J, Berg EM, Sijssens KM, Rothova A. Subfoveal serous retinal detachment in patients with uveitic macular edema. Arch Ophthalmol. 2011;129(2):158-62.
67. Matsuo T, Himei K, Ichimura K, Yanai H, et al. Long-term effect of external beam radiotherapy of optic disc hemangioma in a patient with von Hippel-Lindau disease. Acta Med Okayama. 2011;65(2):135-41.
68. Mandal S, Naithani P, Venkatesh P, Garg S. Intravitreal bevacizumab (avastin) for circumscribed choroidal hemangioma. Indian J Ophthalmol. 2011;59(3):248-51.
69. Shukla D, Kanungo S, Prasad NM, Kim R. Surgical outcomes for vitrectomy in Eales' disease. Eye (Lond). 2008;22(7):900-4.